WEBULL

DKSH Holding (SWX:DKSH) Could Be 7% Below Fair Value After Eli Lilly Deal

Simply Wall St · 1d ago

DKSH Holding (SWX:DKSH) is in focus after its healthcare unit signed an agreement with Eli Lilly Export S.A. to sell, promote, and distribute Lilly’s pharmaceutical portfolio in Hong Kong and Macau.

See our latest analysis for DKSH Holding.

The Lilly agreement comes at a time when DKSH Holding’s momentum has been firm, with a 30 day share price return of 8.16% and a year to date share price return of 15.36%, while the 1 year total shareholder return of 18.60% points to steady longer term gains.

If this kind of healthcare partnership has your attention, it may be worth widening your search using a focused list of pharma and biotech distributors and checking out 106 top founder-led companies

Bulls see the Lilly deal as fresh proof that DKSH Holding’s healthcare platform is still winning meaningful mandates, while bears worry recent share gains already reflect that. Which side does the current valuation appear to favor?

Most Popular Narrative: 6.9% Undervalued

On the most followed narrative, DKSH Holding’s fair value of CHF72.57 sits above the last close at CHF67.60, which places the Lilly agreement within a broader earnings story.

DKSH's accelerated M&A strategy, supported by a near debt-free balance sheet and a strong deal pipeline, underpins inorganic growth, network expansion, and access to higher-margin service offerings, all of which are expected to drive earnings growth over the coming years.

Read the complete narrative.

The narrative points to modest revenue growth, improving margins, and a richer profit multiple as key factors behind the fair value target.

Result: Fair Value of CHF72.57 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, DKSH Holding’s story could change quickly if consumer demand in Asia Pacific stays weak, or if currency swings and heavier M&A activity squeeze margins.

Find out about the key risks to this DKSH Holding narrative.

Another View: DKSH Holding Through a Market Multiple Lens

While the SWS DCF model suggests DKSH Holding is trading about 28.5% below an estimated fair value of CHF94.59, the market is pricing the stock on a richer P/E of 21.7x versus 19x for the European Trade Distributors industry and a fair ratio of 21.4x. This points to only a slim margin of error if earnings disappoint. Which signal do you trust more when the next piece of news lands?

For a closer look at how this P/E gap compares with peers and what it might mean for valuation risk, See what the numbers say about this price — find out in our valuation breakdown.

SWX:DKSH P/E Ratio as at Jul 2026
SWX:DKSH P/E Ratio as at Jul 2026

Next Steps

If this DKSH Holding story has raised as many questions as answers, consider taking a closer look at the positives investors are already focused on and see what stands out to you in the data. To understand what those potential bright spots are, review the 3 key rewards

Looking for more investment ideas beyond DKSH Holding?

If DKSH Holding has sharpened your focus, do not stop here. There are other opportunities worth checking using the Simply Wall Street Screener before the market moves.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.